Qiagen (QGEN) Investor presentation summary

Q1 2026 financial performance

• Net sales reached $492 million, up 2% actual but down 1% at constant exchange rates (CER), with adjusted diluted EPS at $0.54, in line with outlook.

• Sample technologies grew 9% CER, with Parse integration progressing and on track to exceed $40 million FY 2026 sales target.

• QIAcuity achieved double-digit CER growth, driven by instrument placements and consumables expansion.

• QuantiFERON sales declined 5% CER due to sharply lower immigration testing demand, while other patient testing groups showed solid trends.

• Adjusted operating income margin was 27.4%, absorbing 3.4 percentage points of headwinds from tariffs, currency, and acquisitions.

Product and portfolio developments

• Launch of Evercode Whole Transcriptome chemistry by Parse enables scalable single-cell sequencing up to 5 million cells.

• Oncology portfolio expanded with new QIAseq panels and AI-grounded solutions for drug discovery.

• QIAstat-Dx advanced with new panels, including blood culture for bloodstream infection testing in Europe and expanded GI panels in the U.S.

Updated 2026 outlook and growth drivers

• FY 2026 net sales growth expected at ~1-2% CER, with H2 2026 anticipated to deliver ~4% CER growth.

• Four out of five growth pillars delivered or exceeded expectations in Q1 2026; QuantiFERON target revised downward due to immigration testing headwinds.

• Adjusted diluted EPS for FY 2026 expected to be at least $2.43 CER.

• Q2 2026 outlook projects ~-2% CER net sales, with positive currency impact of ~1 percentage point.